Publications by authors named "S J Hiom"
Article Synopsis
- Cancer research is hindered by the need for high-quality, resource-intensive data, and this study compares on-site diagnostic cancer data collected during the SYMPLIFY study with existing cancer registry data from England and Wales to evaluate its validity and timeliness.
- Data from over 5,400 participants was analyzed, focusing on the relevance and timeliness of cancer diagnoses made within nine months of enrollment, covering various classifications including ICD-10 codes, morphology, stage, and TNM classification.
- Findings revealed high levels of data completeness (84%-100% for morphology), but lower completeness for overall stage (43%-100%) and TNM stage (74%-83%), with a notable concordance rate
Background: Analysis of circulating tumour DNA could stratify cancer risk in symptomatic patients. We aimed to evaluate the performance of a methylation-based multicancer early detection (MCED) diagnostic test in symptomatic patients referred from primary care.
Methods: We did a multicentre, prospective, observational study at National Health Service (NHS) hospital sites in England and Wales.
Background: Timely diagnosis of cancer in patients who present with symptoms in primary care is a quality-improvement priority.
Aim: To examine possible changes to aspects of the diagnostic process, and its timeliness, before and after publication of the National Institute for Health and Care Excellence's (2015) guidance on the referral of suspected cancer in primary care.
Design And Setting: Comparison of findings from population-based clinical audits of cancer diagnosis in general practices in England for patients diagnosed in 2018 or 2014.
Background: Unlicensed medicines are used across the UK to treat an individual's clinical needs when there are no appropriate licensed alternatives. Patients, carers and parents have reported facing challenges with unlicensed medicines at the points of transfer of care between settings, a key time when medication errors may occur. There is little known about the patient journey as a whole, or the factors affecting patient care when receiving an unlicensed medicine.
View Article and Find Full Text PDF